Non-Surgical Treatment of Peri-implantitis with Systemic Azithromycin or Placebo

The primary objective of this study is to evaluate the change in probing depth in patients with peri-implantitis, assessing the influence of systemic antibiotic (azithromycin) adjunctive to non-surgical treatment at 12 months. The secondary objective is to assess clinical, radiographic, microbiological, and systemic changes at 3, 6, and 12 months. This study is designed as a placebo-controlled, randomized, triple-blind clinical trial in subjects diagnosed with peri-implantitis. The treatment will consist of debridement of the implant surface and curettage of the pocket epithelium. The control group will receive placebo (1 placebo tablet per day for 3 days), and the test group will receive systemic azithromycin 500 mg per day for 3 days (1 tablet of 500 mg azithromycin per day for 3 days).

NCT Number	NCT06715150
Lead Sponsor	University of Santiago de Compostela
Conditions	Peri-implantitis
Enrollment	52 participants
Start Date	2025-01-10
Primary Completion	2026-01-10 (estimated)
Study Completion	2027-01-10 (estimated)
Updated on ClinicalTrials.gov	2024-12-10